Plasma levels of omentin-1 and visfatin in senile patients with coronary heart disease and heart failure

Asian Pacific Journal of Tropical Medicine

Volumn 7, Issue 1, 2014, Pages 55-62

  Wang, Xiu Hua ^a   Dou, Ling Zhi ^a   Gu, Can ^a   Wang, Xiao Qing ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Coronary heart disease; NYHA class; Omentin 1; Stable angina pectoris; Unstable angina pectoris; Visfatin

Indexed keywords

ADIPOCYTOKINE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OMENTIN 1; UNCLASSIFIED DRUG;

AGED; AGING; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; STABLE ANGINA PECTORIS; SYSTOLIC BLOOD PRESSURE; UNSTABLE ANGINA PECTORIS;

CORONARY HEART DISEASE; NYHA CLASS; OMENTIN-1; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS; VISFATIN;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANGINA PECTORIS; CORONARY DISEASE; CYTOKINES; GPI-LINKED PROTEINS; HEART FAILURE; HUMANS; LECTINS; LINEAR MODELS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

EID: 84892180272     PISSN: 19957645     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1995-7645(13)60192-3     Document Type: Article

References (37)

1. Lago F, Dieguez C, Gómez-Reino J, Gualillo O The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine & Growth Factor Rev 2007, 18(3-4):313-325.
2. Yang R, Xu A, Hu JPH, Jadhao S, Hansen B, Shuldiner A, et al. Cloning of omentin, a new adipocytokine from omental fat tissue in humans. Diabetes 2003, (Suppl. 1):A1. (1-OR).
3. Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011, 408(2):339-343.
4. Kazama K, Usui T, Okada M, Hara Y, Yamawaki H Omentin plays an anti-inflammatory role through inhibition of TNF-alpha-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol 2012, 686(1-3):116-123.
5. Shang FJ, Wang JP, Liu XT, Zheng QS, Xue YS, Wang B, et al. Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Biomarkers 2011, 16(8):657-662.
6. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307(5708):426-430.
7. Sonoli SS, Shivprasad S, Prasad CV, Patil AB, Desai PB, Somannavar MS, et al. Visfatin-a review. Eur Rev Med Pharmacol Sci 2011, 15(1):9-14.
8. De Luis DA, Gonzalez SM, Conde R, Aller R, Izaola O, Castro MJ, et al. Lack of effect of a moderate hypocaloric diet on visfatin levels in morbid obese patients: relationship with insulin resistance. Eur Rev Med Pharmacol Sci 2010, 14(12):1031-1036.
9. Malyszko J, Malyszko JS, Mysliwiec M Visfatin and endothelial function in dialyzed patients. Nephrology (Carlton) 2010, 15(2):190-196.
10. Dahl TB, Yndestad A, Skjelland M, Oie E, Dahl A, Michelsen A, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007, 115(8):972-980.
11. Fain JN, Sacks HS, Buehrer B, Bahouth SW, Garrett E, Wolf RY, et al. Identification of omentin mRNA in human epicardial adipose tissue: comparison to omentin in subcutaneous, internal mammary artery periadventitial and visceral abdominal depots. Int J Obes (Lond) 2008, 32(5):810-815.
12. Feng X, Xu Y Relationship between plasma P-selectin and coronary heart disease. Chin J Postgraduates Med 2009, 32(34).
13. Zhong X, Zhang HY, Tan H, Zhou Y, Liu FL, Chen FQ, et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin 2011, 32(7):873-878.
14. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006, 290(6):E1253-E1261.
15. Cai R, Wei L, Wu H, Bao YQ, Jia WP, Xiang KS Serum omentin level and related factors in obese and type 2 diabetic patients. National Med J Chin 2008, 88(16):1096-1099.
16. Duan XY, Xie PL, Ma YL, Tang SY Omentin inhibits osteoblastic differentiation of calcifying vascular smooth muscle cells through the PI3K/Akt pathway. Amino Acids 2011, 41(5):1223-1231.
17. Xie H, Xie PL, Wu XP, Chen SM, Zhou HD, Yuan LQ, et al. Omentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expression. Cardiovasc Res 2011, 92(2):296-306.
18. Shibata R, Ouchi N, Kikuchi R, Takahashi R, Takeshita K, Kataoka Y, et al. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis 2011, 219(2):811-814.
19. El SW, El TL, Meki AR, Abdel Moneim A Proinflammatory cytokines, soluble Fas receptor, nitric oxide and angiotensin converting enzyme in congestive heart failure. Egypt J Immunol 2005, 12(1):39-48.
20. Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011, 408(2):339-343.
21. Zhong X, Li X, Liu F, Tan H, Shang D Omentin inhibits TNF-alpha-induced expression of adhesion molecules in endothelial cells via ERK/NF-kappaB pathway. Biochem Biophys Res Commun 2012, 425(2):401-406.
22. Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006, 49(4):744-747.
23. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A Insulin resistance in hepatocytes and sinusoidal liver cells: Mechanisms and consequences. J Hepatol 2007, 47(1):142-156.
24. Ooi SQ, Chan RM, Poh LK, Loke KY, Heng CK, Chan YH, et al. Visfatin and its genetic variants are associated with obesity-related morbidities and cardiometabolic risk in severely obese children. Pediatr Obes 2013.
25. Pillai VB, Sundaresan NR, Kim G, Samant S, Moreno-Vinasco L, Garcia JG, et al. Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling. Am J Physiol Heart Circ Physiol 2013, 304(3):H415-H426.
26. Lim SY, Davidson SM, Paramanathan AJ, Smith CC, Yellon DM, Hausenloy DJ The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med 2008, 12(4):1395-1403.
27. Segawa K, Fukuhara A, Hosogai N, Morita K, Okuno Y, Tanaka M, et al. Visfatin in adipocytes is upregulated by hypoxia through HIF1α-dependent mechanism. Biochem Biophys Res Comm 2006, 349(3):875-882.
28. Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011, 27(6):515-527.
29. Yang Y, Yang G, Li L, Zhang L, Miao ZY, Lu HM Effects of visfatin on insulin resistance and expression of related genes in rats. Medical J Chin Peoples Liberation Army 2009, 34(4).
30. Li R, Yang G, Li L, Sun Q, Liu JL, Shi SC, et al. Effects of plasma visfatin levels on cholesterol metabolism in liver and SREBP-2 in rats. J Fourth Military Med Univ 2008, 29(15):1382-1384.
31. Zhang Y, Li L, Yang G, Lu CM Effects of visfatin down-regulation on lipid metabolism in 3T3-L1 cells and heipal-6 cells. Chin J Gerontol 2013, 33(01):77-79.
32. Sethi JK, Vidal-Puig A Visfatin: the missing link between intra-abdominal obesity and diabetes?. Trends Mol Med 2005, 11(8):344-347.
33. Mu J, Feng B, Ye Z, Yuan F, Zeng W, Luo Z, et al. Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease. J Nephrol 2011, 24(2):177-184.
34. Kim JY, Bae YH, Bae MK, Kim SR, Park HJ, Wee HJ, et al. Visfatin through STAT3 activation enhances IL-6 expression that promotes endothelial angiogenesis. Biochim Biophys Acta 2009, 1793(11):1759-1767.
35. Liu SW, Qiao SB, Yuan JS, Liu DQ Visfatin stimulates production of monocyte chemotactic protein-1 and interleukin-6 in human vein umbilical endothelial cells. Horm Metab Res 2009, 41(4):281-286.
36. Tang FK, Hua N, Lu H, Xiao J, Tang XZ, Qi Z Effects of bisoprolol on serum interleukin-6 and tumor necrosis factor-alpha level in patients with congestive heart failure. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2008, 24(12):1177-1179.
37. Kim S, Bae Y, Bae S, Choi K, Yoon K, Koo T, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-κB activation in endothelial cells. Biochimica etBiophysica. Acta MolCell Res 2008, 1783(5):886-895.